Who
Khalid Islam
Director
Company insider
Files Form 4 as: Executive Chairman, Gain Therapeutics; Director, Fennec Pharmaceuticals; Director, Processa Pharmaceuticals; Director, Immunomedics.
In numbers
- Trades disclosed
- 37
- Buys
- 1
- Sells
- 0
- Bought
- $50K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 3 Jul 2017
- Last trade
- 15 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jul 2026filed 17 Jul 2026 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 10 Jun 2026filed 10 Jun 2026 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $218K25,000 at $8.70 | filing |
| 10 Jun 2026filed 10 Jun 2026 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $218K25,000 at $8.70 | filing |
| 24 Jun 2025filed 25 Jun 2025 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 3 Jun 2025filed 4 Jun 2025 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $197K25,000 at $7.88 | filing |
| 15 Aug 2024filed 19 Aug 2024 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $140K25,000 at $5.58 | filing |
| 9 Aug 2024filed 12 Aug 2024 | GANX Gain TherapeuticsBiotechnology | SEC FORM 4 Bought | $50K50,000 at $1.00 | filing |
| 24 Jun 2024filed 26 Jun 2024 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 16 Nov 2023filed 16 Nov 2023 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | $308K133,333 at $2.31 | filing |
| 16 Nov 2023filed 16 Nov 2023 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | $27K10,000 at $2.69 | filing |
| 16 Nov 2023filed 16 Nov 2023 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | $57K50,000 at $1.13 | filing |
| 16 Nov 2023filed 16 Nov 2023 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | $50K20,492 at $2.44 | filing |
| 16 Nov 2023filed 16 Nov 2023 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $308K133,333 at $2.31 | filing |
| 16 Nov 2023filed 16 Nov 2023 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $27K10,000 at $2.69 | filing |
| 16 Nov 2023filed 16 Nov 2023 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $57K50,000 at $1.13 | filing |
| 16 Nov 2023filed 16 Nov 2023 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $50K20,492 at $2.44 | filing |
| 23 Jun 2023filed 26 Jun 2023 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 12 Jun 2023filed 13 Jun 2023 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 20 Sep 2022filed 22 Sep 2022 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.